A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Pimozide

Typical Antipsychotic class · 1 generic manufacturer · 2 ANDAs filed at FDA.

First FDA approval2015-09-28
Generic availableYes · 1 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$2.1M in CY2024 Part D spend16K claims · 4K beneficiaries · 329 plans surveyed

Lowest NADAC
$1.25/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$1.48
Across all dosage forms in distribution.
Highest NADAC
$1.71
Range is tight.
Plans with PA
88 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Pimozide used for?

Pimozide is a Typical Antipsychotic medication tracked in Medicare Part D.

Is there a generic for Pimozide?

Yes. 2 ANDAs filed at FDA, 1 generic manufacturers currently shipping.

How much does my plan pay for Pimozide?

Across 329 Part D plans, Pimozide averages $1.48/unit (NADAC). Lowest available: $1.25/unit. Highest in distribution: $1.71/unit.

Is Pimozide on the FDA shortage list?

No. Pimozide is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Typical Antipsychotic2 alternatives in D1
01
Haloperidol
Brand: HALOPERIDOL
$0.123Lowest NADAC
21Generic mfrs
$39.4MCY24 Part D spend
Compare →
02
Thiothixene
Typical Antipsychotic
$0.659Lowest NADAC
3Generic mfrs
$3.3MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.